Amer A. Beg
Affiliations: | Columbia University, New York, NY |
Area:
Immunology, MicrobiologyGoogle:
"Amer Beg"Children
Sign in to add trainee| Ye Zheng | grad student | 2003 | Columbia |
| Junmei Wang | grad student | 2010 | Columbia |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ibrahim ML, Zheng H, Barlow ML, et al. (2024) Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors. Journal of Immunology (Baltimore, Md. : 1950) |
| Han T, Jiang S, Zheng H, et al. (2019) Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. Nature Communications. 10: 3716 |
| Gray JE, Saltos AN, Tanvetyanon T, et al. (2019) Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Stewart PA, Welsh EA, Slebos RJC, et al. (2019) Proteogenomic landscape of squamous cell lung cancer. Nature Communications. 10: 3578 |
| Xie M, Zheng H, Madan-Lala R, et al. (2019) MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer. Cancer Research |
| Saltos AN, Tanvetyanon T, Haura EB, et al. (2019) Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results. Journal of Clinical Oncology. 37: 9073-9073 |
| Xie M, Zheng H, Madan-Lala R, et al. (2019) Abstract B072: MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer Molecular Cancer Therapeutics |
| Xie M, Zheng H, Beg A. (2017) Abstract 5662: MEK inhibitors potentiate tumor immune surveillance by enhancing cancer cell response of IFNγ Cancer Research. 77: 5662-5662 |
| Cohen AS, Doligalski ML, Zheng H, et al. (2017) Abstract 1709: Targeting immune checkpoint therapy to the lung tumor microenvironment Cancer Research. 77: 1709-1709 |
| Zheng H, Zhao W, Yan C, et al. (2016) HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |